News

Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program

Ad hoc announcement pursuant to Art. 53 LR Management call today at 3.30 pm CEST Newron received the anticipated FDA written communication on clinical hold at U.S. study centers

Newron Provides Update on Phase 3 ENIGMA-TRS 2 Study

Ad hoc announcement pursuant to Art. 53 LR U.S. clinical hold remains in place; study continues in all other countries Company initiates expansion of clinical sites and enrollment

Newron presents H1 2026 results and provides corporate update

Ad hoc announcement pursuant to Art. 53 LR Milan, Italy, and Morristown, NJ, USA – September 22, 2026, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA:

Newron reports subscription for EUR 5.5 million of shares by investor group as part of up to EUR 38 million total financing to advance Phase 3 evenamide program

Ad hoc announcement pursuant to Art. 53 LR Total proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development

Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Milan, Italy, and Morristown, NJ, USA, September 3, 2026, – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the

Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)

Ad hoc announcement pursuant to Art. 53 LR ENIGMA-TRS 1 is Phase 3 international, one-year, randomized, double-blind, placebo-controlled study in 600+ patients; 12-week study

Newron provides update following Type A meeting with the FDA

Ad hoc announcement pursuant to Art. 53 LR Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in

Newron Pharmaceuticals to Participate in June Investor Conferences

Milan, Italy, and Morristown, NJ, USA – May 28, 2026, 3:30 pm CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the

Newron reports a pause in enrollment of new study participants in US centers of ENIGMA-TRS 2 study

Ad hoc announcement pursuant to Art. 53 LR Newron reports a pause in enrollment of new study participants in US centers of ENIGMA-TRS 2 study Pause of enrollment limited to US

Newron announces AGM 2026 results

Newron announces AGM 2026 results Milan, Italy, April 23, 2026, 3:10 pm CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused